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Introduction:  Valvular  heart  disease  (VHD)  is increasing  worldwide,  mostly  because  of  aging.
Percutaneous  valve  intervention  is  the preferred  therapeutic  option  in high-risk  patients.
Objective: To  characterize  the  profiles  of  patients  with  VHD admitted  to  the  cardiology  ward
at a  tertiary  referral  center.
Methods:  On the  basis  of  ICD-9  codes  for  VHD,  the  discharge  notes  of  287  patients  hospital-
ized  over  a 22-month  period  were  reviewed  and  analyzed.  One  hundred  characteristics  were
considered.
Results: Median  age  was  74  (23-93)  years,  and  145  (51%)  were  male.  The  admissions  were  elec-
tive (for  valve  intervention)  in  36%.  Heart  failure  (HF)  was  the  reason  for  urgent  admissions  in
29.3%. Multiple  comorbidities  were  observed  in 53%  of  patients.  Etiology  of  VHD  was  degenera-
tive in  68%,  functional  in 15.3%  and  rheumatic  (predominantly  in women  and  younger  patients)
in 8.7%.  Aortic  valve  disease  was  present  in 63%  (aortic  stenosis  in  56%),  and  was  associated
with HF (p=0.004),  atrial  fibrillation  (AF)  (p=0.01),  and left  ventricular  (LV)  dilatation  (p=0.003)
or hypertrophy  (p<0.001).  Mitral  valve  disease  (51%),  mostly  mitral  regurgitation  (degenerative
or functional),  predominated  in  women,  and  was  associated  with  HF,  AF,  LV  dilatation  (p<0.001)
and reduced  LV  ejection  fraction  (p=0.003).  Significant  tricuspid  regurgitation  (34.8%)  associ-
ated with  the  presence  of  previously  implanted  cardiac  devices  (p<0.001).  Valve  intervention
(mostly transcatheter  aortic  valve  implantation)  was  performed  in 41%  of  patients.  Mean  length
of hospital  stay  was  12±14.3  days and overall  in-hospital  mortality  was  9.8%.
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Conclusions:  Nowadays,  the  profiles  of hospitalized  patients  with  VHD are  dominated  by  the
elderly, with  degenerative  disease  and  multiple  comorbidities,  presenting  with  HF,  AF and  LV
remodeling, who  frequently  undergo  valve  intervention,  usually  via  a  percutaneous  approach.
Mortality remains  significant  in  this high-risk  population.
©  2018  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is an









Perfis  de doentes  hospitalizados  com  doença cardíaca  valvular:  experiência  de um
centro  terciário
Resumo
Introdução:  A  doença  cardíaca  valvular  (DCV)  é problema  crescente,  relacionando-se  com  o
envelhecimento  populacional.  A  intervenção valvular  por via  percutânea  é  opção preferencial
em alguns  contextos,  inclusive  em  doentes  de  elevado  risco.
Objetivo:  Caracterização  do perfil  dominante  do  doente  com  DCV  admitido  em  enfermaria  de
cardiologia (centro  terciário  de referência).
Métodos:  Revisão  de  processos  clínicos  de  287  doentes  (códigos  ICD-9  para  DCV)  internados  num
período de  22  meses.  Foram  consideradas  para  análise  100  características.
Resultados:  Idade  -  74  (23-93)  anos;  145  (51%)  homens.  Admissões  eletivas  (intervenção valvu-
lar): 36%.  Insuficiência  cardíaca  (IC):  causa  de admissão  urgente  em  29,3%.  Comorbilidades
múltiplas: 53%  dos  doentes.  Etiologias:  degenerativa  (68%);  funcional  (15,3%);  reumática
(8,7%) -- predominantemente  em  mulheres  e  em  doentes  mais  jovens.  Doença  valvular  aór-
tica -  63%  (estenose  em  56%),  associou-se  à  presença  de IC (p  = 0,004),  fibrilhação  auricular
(FA)- p  =  0,014  --  e hipertrofia  (p  <  0,001)  ou dilatação  ventricular  esquerda  (VE)  --  p  =  0,003.
Doença valvular  mitral  (51%)  -  predominantemente  regurgitação  -  degenerativa  ou  funcional,
mais frequente  em  mulheres;  associou-se  à  presença  de  IC, FA,  dilatação  VE  --  p  <  0,001  -
e fração  de  ejeção VE  diminuída  (p  = 0,003).  Insuficiência  tricúspide  (34,8%),  associou-se  à
presença de  eletrocatéteres  previamente  implantados  (p  <  0,001).  Intervenções valvulares:  41%
dos doentes,  predominantemente  TAVI.  Duração  de internamento:  12  ± 14,3  dias;  mortalidade
global intra-hospitalar:  9,8%.
Conclusões:  O perfil  atual  do  doente  hospitalizado  com  DCV  é dominado  pelo  idoso  com  doença
degenerativa  e  múltiplas  comorbidades,  apresentando  remodelagem  VE,  IC  e FA,  e sendo  fre-
quentemente  submetido  a  intervenção valvular  (predominantemente  por  via  percutânea).  A
mortalidade  é significativa  nessa  população  de risco  elevado.
© 2018  Sociedade  Portuguesa  de Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é um
artigo Open  Access  sob  uma licença  CC BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Valvular  heart  disease  (VHD)  has recently  been  described
as  ‘‘the  next  cardiac  epidemic’’,1 in particular  due  to  its
increased  prevalence  in  the elderly  mainly  from  degen-
erative  causes  in industrialized  countries.1,2 However,
rheumatic  etiology  is  still  the  most  frequent  cause  of  VHD
in  developing  countries  and predominantly  affects  younger
populations.3
The  epidemiology  of VHD  is  especially  difficult  to  study
as  most  cases  run their  natural  history  without  significant
symptoms  for  varying  periods  of  time,  and imaging  studies
(particularly  echocardiography)  are  required  for  accurate
diagnosis  and  characterization.2,3 Based  on  data  from
large  population-based  epidemiological  studies  in  the  USA
which  included  individuals  from  the  general  population  who
had  been  assessed  prospectively  with  echocardiography,3
the estimated  prevalence  of significant  VHD in developed
countries  is  2.5%. Mitral  regurgitation  (MR) was  found  to
be the  most  frequent  VHD,  especially  in the elderly.3
However,  in the Euro  Heart  Survey,  a prospective  study  con-
ducted  in 25  European  countries  that  included  inpatients
and  outpatients  with  moderate  to  severe  VHD,  infective
endocarditis,  or  prior  valve  intervention,4 the most  fre-
quent  VHD  (43.1%)  was  aortic  stenosis  (AS),  predominantly  of
degenerative  cause. Rheumatic  etiology  was  found in  22%  of
cases.4
Published  data  clearly  show  a  high  prevalence  of  AS and
MR  in industrialized  countries,  where  VHD  mainly  affects
the  elderly  population  due  to  increased  life  expectancy,
and  in  association  with  functional  and  structural  cardiac
abnormalities.2,5 VHD  is  linked  to  significant  cardiovascular
and  all-cause  mortality,  independently  of ventricular  func-
tion  and  comorbidities.5
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Degenerative  AS,  a  consequence  of  a  continuous  process
of  valve  sclerosis  and  calcification,6 increases  significantly
in  prevalence  with  age,2,3,6,7 and  around  40%  of individu-
als  aged  over  75  years  are  estimated  to  have a  calcified
aortic  valve.  When  intervention  is  indicated,  the deci-
sion  between  surgical  aortic  valve  replacement  (SAVR)  or
transcatheter  aortic  valve  implantation  (TAVI)  should  be
made  by  the  heart team  according  to  the  individual  patient’s
characteristics.8
Functional  MR  is  the most  frequent  valve  disease  in
the  USA,3,9,10 as  a consequence  of  the left ventricular  (LV)
remodeling  and  dilatation  commonly  seen  in  both  non-
ischemic  cardiomyopathy  (mostly  due  to  hypertensive  heart
disease  or  idiopathic  dilated  cardiomyopathy)  and ischemic
heart  disease.10 As  the prevalence  of heart  failure  (HF)  is
increasing,  functional  MR  is  also  likely  to  increase  in the
future.  In patients  with  severe  primary  or  secondary  (func-
tional)  MR,  in addition  to  optimal  medical  management  of
HF,11 valve  repair  or  replacement  may  be  necessary,  and  the
recent  advent  of percutaneous  techniques  has  provided  an
effective  and safe way  of  improving  HF symptoms  in  suitable
candidates.8,11,12
In  developing  countries  rheumatic  heart  disease  (which
mainly  affects  the mitral  valve)  is  still  the  major cause  of
VHD,  due  to  the persistently  high  prevalence  of  rheumatic
fever,  and  is  associated  with  reduced  life  expectancy.2,13,14
The  prevalence  of  rheumatic  heart  disease  in developed
countries  has decreased,  but  as  degenerative  valve  disease
affecting  the  elderly  is  increasing,14 the burden  of  VHD  will
is  likely  to  grow  substantially  in  the future.3
The  present  study  aims  to  characterize  the current  pro-
files  of  patients  with  significant  VHD  admitted  over  a period
of  22  consecutive  months  to  the cardiology  ward  at a  large




Patient  data  were  acquired  by  searching  for  electronic
discharge  notes  coded  with  a diagnosis  of  valve  disease
according  to  the International  Classification  of  Diseases,
Ninth  Revision  (ICD-9)  of all  patients  admitted  to  the car-
diology  ward  in the Cardiology  Department  of  Santa  Maria
University  Hospital  between  January  1, 2014  and  October  3,
2015  (see  Appendix  1 for  details).
The  search  identified  391  patients,  whose  discharge  notes
were  then  manually  reviewed.  Only  patients  with  signif-
icant  VHD  and  those  with  prior  heart  valve  interventions
were  selected.  Accordingly,  only  patients  who  underwent
echocardiographic  assessment  during  the hospitalization
under  study  (index  hospitalization)  were  included.
Significant  VHD  was  defined  on  the  basis  of  clinical
plus  imaging  criteria  (mainly  echocardiography),15,16 and
included  moderate  to severe  valvular  stenosis  and/or  regur-
gitation  of  any  cardiac  valve  (or  multiple  valves)  that  was
responsible  in any  way  for the index  hospitalization.  Left
ventricular  ejection  fraction  (LVEF)  was  considered  to  be
reduced  if <50%.17
Study  population  and design
In accordance  with  the above  criteria,  66  patients  were
excluded  for  presenting  only  mild  valvular  disease;  addition-
ally,  38  patients  were  also  excluded  because  of  insufficient
information  available  in  the system  (patients  admitted  elec-
tively  to  undergo  selective  examinations  only  or  patients
with  hospital  stay  less  than  24  hours).  The  final  study  popu-
lation  included  287 patients.
Discharge  notes  of  these  patients  were  carefully  manu-
ally  reviewed.  In  addition  to  characterization  of  VHD  (valves
involved,  disease  severity  and  etiology)  on  the  basis  of all
the available  information,  the following  data  were  collected
and  analyzed:  demographics  (gender,  age,  ethnicity,  place
of  birth),  admission  and  discharge  dates,  type  of  admission
to  the  cardiology  ward  (elective  or  urgent),  main  reason  for
hospital  admission,  length  of  hospital  stay  (LOS),  major  car-
diovascular  risk  factors  (systemic  hypertension,  diabetes,
dyslipidemia,  smoking),  presence  and  type  of  comorbidities,
history  of chronic  HF and New York  Heart  Association  (NYHA)
functional  class,  presence  of advanced  atrioventricular  (AV)
block,  bundle  branch  block  (BBB)  or  atrial  fibrillation  (AF)
(chronic  or  new-onset),  presence  of pulmonary  hyperten-
sion  (assessed  invasively  or  by  echocardiography),  coronary
artery  disease  (CAD)  (assessed  by  coronary  angiography),
coronary  artery  bypass grafting  (CABG)  during  the  index
admission,  implanted  cardiac  devices  (during  the index  hos-
pitalization  or  in the past),  valvular  intervention  (during
the  index  hospitalization  or  in the  past),  hospital  admis-
sions  due  to  VHD  in the 12  months  preceding  the index
hospitalization,  mortality  (and  cause  of  death)  during  the
index  hospitalization,  and  destination  after  discharge.  Var-
ious  echocardiographic  parameters  and  indices  (assessed
during  the  index hospitalization  before any  new  valvular
intervention)  were  also  collected,  including  cardiac  cham-
ber  size  and  measures  of  systolic  LV and  right  ventricular
(RV)  function.
In  addition  to  the  descriptive  data,  we  looked  for
associations  between  the type and etiology  of VHD  and
demographic,  clinical,  electrocardiographic  and echocar-
diographic  features,  in order  to  improve  characterization
of  the  profiles  of  hospitalized  patients  with  VHD.
Statistical  analysis
The  statistical  analysis  was  performed  with  Microsoft  Excel
2013
®
and  IBM  SPSS
®
version  22.0.  A  descriptive  analy-
sis  of the  different  variables  was  performed  and  possible
differences  between  genders  were  assessed.  Quantitative
variables  are  expressed  as  means  ±  standard  deviation,
and  qualitative  variables  as  absolute  or  relative  frequencies
(percentages).  The  Student’s  parametric  t  test for indepen-
dent  variables  was  used  to  compare  quantitative  variables  as
a  function  of  the  presence  and type  of VHD  (mitral,  aortic,
mitral-aortic  or  tricuspid  valve  disease).  Categorical  varia-
bles  were analyzed  using  the  chi-square  test  and  Fisher’s
exact  test,  as  appropriate.  Possible  associations  between
type  of  VHD  and demographic,  clinical,  electrocardiographic
and  echocardiographic  features  were  analyzed  using Pear-
son’s correlation  test.
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Table  1  Population  with  valvular  heart  disease:  character-
istics and  procedures.
Echocardiographic  data
Reduced  LVEF,  n  (%)  96  (33.4%)
LV  dilatation,  n  (%)  69  (24%)
LV  hypertrophy,  n (%) 157  (54.7%)
LV hypertrophy  plus  dilatation,  n  (%) 19  (6.6%)
RV  dilatation,  n  (%) 47  (16.4%)
RV  hypertrophy,  n  (%)  3  (1%)
RV hypertrophy  plus  dilatation,  n  (%)  2  (0.7%)
Reduced  TAPSE,  n  (%)  35  (12.2%)
LA  dilatation,  n  (%)  228  (79.4%)
RA dilatation,  n  (%)  135  (47%)
LA plus  RA  dilatation,  n  (%)  129  (44.9%)
Cardiac devices
Previously  implanted,  n  (%)  48  (16.7%)
PM,  n (%) 30  (10.5%)
ICD,  n (%)  10  (3.5%)
CRT-P,  n  (%)  1  (0.3%)
CRT-D,  n (%)  7  (2.4%)
Implanted  during  index  hospitalization,  n (%) 55 (19.2%)
PM,  n (%) 51  (17.8%)
ICD,  n (%) 2  (0.7%)
CRT-P,  n  (%) 2  (0.7%)
CRT-D,  n (%) 0
Procedures  and  interventions  related  to  CAD
Coronary  angiography  performed,  n  (%)  105  (36.6%)
PCI, n  (%)  28  (9.8%)
CABG,  n  (%)a 4  (1.4%)
Valve interventions
Prior  to  index  hospitalization,  n (%)  31  (10.8%)
Aortic  valve,  n  (%)  18  (58.1%)
Mitral  valve,  n  (%)  16  (51.6%)
Tricuspid  valve,  n  (%) 1  (3.2%)
Surgery  with  prosthesis  implantation,  n (%)  18  (58.1%)
Surgery  with  valve  repair,  n  (%)  12  (38.7%)
TAVI,  n  (%)  4  (12.9%)
MitraClip  procedure,  n (%)  0
During index  hospitalization,  n  (%)  118  (41.1%)
Aortic valve,  n  (%)  99  (83.9%)
Mitral  valve,  n  (%)  20  (16.9%)
Tricuspid  valve,  n  (%) 1  (0.8%)
Surgery  with  prosthesis  implantation,  n (%)  15  (12.7%)
Surgery  with  valve  repair,  n  (%)  7  (5.9%)
TAVI, n  (%)  77  (65.3%)
MitraClip  procedure,  n (%)  11  (9.3%)
CABG: coronary artery bypass grafting; CAD: coronary artery
disease; CRT-D: cardiac resynchronization therapy defibrilla-
tor; CRT-P: cardiac resynchronization therapy pacemaker; ICD:
implantable cardioverter-defibrillator; LA: left atrium; LOS:
length of hospital stay; LV: left ventricular; LVEF: left ventricular
ejection fraction; PCI: percutaneous coronary intervention; PM:
pacemaker; RA: right atrial; RV: right ventricular; SAVR: surgical
aortic valve replacement; TAPSE: tricuspid annular plane systolic
excursion; TAVI: transcatheter aortic valve implantation.
a Two patients also underwent SAVR.
A p-value  of  <0.05  for  a confidence  interval  of  95%  was
considered  statistically  significant.
Results
Population  characteristics  and interventions  are displayed  in
Table  1.
Population  and  hospitalization-related  data
The  study  population  included  142  females  (49.5%)  and
145  males  (50.5%),  mean  age  74.86±13.39  years  (range
23  to  93),  with  no  difference  between  genders.  Most
patients  were  born  in Portugal  and  11%  were  originally  from
Portuguese-speaking  African  countries.
The  majority  of  patients  were  admitted  through  the
emergency  room  or  by  transfer  from  other  departments
or  hospitals  (66.9%),  while  33.1%  were  elective  admissions.
Fifty-six  patients  (19.51%)  were  hospitalized  for  causes  not
directly  related  to  VHD, primarily  with  acute  coronary  syn-
drome  (ACS)  (71.4%  of  these  cases  and  16.4%  of  all patients
with  VHD),  and  valvular  disease  was  a secondary  diagnosis.
Regarding  all  patients  with  a diagnosis  of VHD,  decom-
pensated  HF  was  the  most  frequent  reason  for  admission
(84  patients,  29.3%).  This  proportion  was  even  higher  in the
group  of 231  patients  admitted  for VHD  (35.5%).  Eighty-four
(36.4%)  were  admitted  electively  for  valve  intervention,  70
(24.4%)  because  of a dysrhythmia  (AF  in 9.1%),  15  (5.2%)  in
the  context  of  a syncopal  episode  (four  of  which  were  due
to  complete  AV  block), and  seven  (2.4%)  due  to  infective
endocarditis.
Forty  patients  (13.9%)  had  been  hospitalized  for  reasons
related  to  VHD  in the 12  months  preceding  the  index  hospi-
talization.
Etiology  and  type  of  valvular  disease
Etiologies  and types  of  valvular  disease  are  shown  in
Figure  1. Most  patients  (67.9%)  had  degenerative  aor-
tic  and/or  mitral  valve  disease,  followed  in frequency
(15.3%)  by  significant  functional  mitral  and/or  tricuspid
regurgitation  (TR)  (secondary  to  left and/or  right  ventric-












Figure  1  Etiologies  of  valvular  heart  disease.  IE:  infectious
endocarditis;  MR:  mitral  regurgitation;  MVP:  mitral  valve  pro-
lapse; TR:  tricuspid  regurgitation;  VHD:  valvular  heart  disease.
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cardiomyopathy).  Rheumatic  etiology  was  diagnosed  in 8.7%
of  patients.  Other  etiologies  included  infectious  endocardi-
tis  (3.8%),  mitral  valve prolapse  (2.8%),  and  congenital  VHD
(0.7%).
Most  patients  with  rheumatic  valve  disease  were women
(84%,  p<0.001),  with  no  significant  gender  differences
observed  in  other  etiologies.  Age  correlated  directly  with
degenerative  etiology  (r=0.473;  p<0.001),  and  inversely  with
rheumatic  disease  (r=-0.36;  p<0.001).
Aortic  valve  disease  was  documented  in  most cases  (181
patients,  63.1%),  of  whom  89% (56%  of all  patients)  had  AS,
and  27.1%  (17.1%  of  all  patients)  had  aortic  valve  regurgita-
tion.  Mitral  disease  was  diagnosed  in  146  patients  (50.9%),
mostly  MR  (90.4%,  46%  of  all  patients);  mitral  stenosis  was
observed  in  15%  of  these  patients  (7.7%  of  all  patients).
Concomitant  aortic  and mitral  valve  disease  was  present  in
22.3%  of  patients.
There  were  no  documented  cases  of  tricuspid  valve
stenosis,  but  significant  TR  was  diagnosed  in 100 patients
(34.8%),  and was  associated  with  mitral  valve  disease  in
69  patients  (69.7%  of patients  with  TR,  24%  of  all  patients).
Isolated  moderate  to  severe  TR  was  observed  in 20  cases
(6.97%).
Moderate  pulmonary  valve  regurgitation  was  infrequent
(13  patients),  and was  diagnosed  in the  context  of  predomi-
nant  mitral  valve  disease  and  TR;  it did  not require  targeted
therapeutic  intervention  in any patient.
Cardiovascular  risk factors and  other  comorbidities
A significant  proportion  of patients  admitted  had  chronic  HF
(39.4%),  and  47.4%  had  chronic  AF. Systemic  hypertension
was  the  most  frequent  cardiovascular  risk  factor  observed,
present  in  219  (76.3%)  patients,  while  177  (61.7%)  patients
had  more  than  one  of  the classical  cardiovascular  risk  fac-
tors.  Multiple  comorbidities  were  found in 53%  of  patients.
The  most  common  was  CAD  (n=81;  28.21%),  followed  by
chronic  kidney  disease  (n=60;  20.9%),  chronic  anemia  (n=76;
26.5%),  chronic  pulmonary  disease  (n=43;  15%)  and  malig-
nancies  (n=39;  13.6%).
Coronary  angiography  was  performed  in  105  (36.6%)  of
patients,  mostly  in the  context  of ACS,  but also  due  to  a
previous  history  of  CAD  or  as  a standard  procedure  before
valve  intervention.  Significant  CAD  was  documented  in  55
(52.4%)  of  cases.  Coronary  revascularization  was  performed
in  32  (11.1%)  patients,  by  a  percutaneous  approach  in  28  and
by  CABG  in  four.
Electrocardiographic  data
AF  was  diagnosed  in 136 (47.4%)  patients,  and  was  signifi-
cantly  associated  with  aortic  valve disease  (p=0.014),  mitral
valve  disease  (p<0.001)  or  TR  (p<0.001).  Advanced  AV  block
was  also  frequent,  with  29  patients  (10.1%)  having  complete
AV  block  at  presentation  (16 patients  with  AS  and 13  with  MR;
AS  and  MR  coexisted  in  five  patients).  Complete  AV  block
was  the  primary  reason  for  pacemaker  implantation  in the
index  hospitalization.  However,  it  was  not a  frequently  doc-
umented  cause  of syncope  on  admission.  Other  causes  of
syncope  at  presentation  were  sinus  node  dysfunction  and
ventricular  tachycardia.
Echocardiographic  data
Reduced  (<50%)  LVEF was  documented  in 33.4%  of patients
and  was  associated  with  mitral  disease  (p=0.003).  In  12.2%
of  patients  RV  longitudinal  systolic  function  assessed  by  tri-
cuspid  annular  plane systolic  excursion  (TAPSE)  was  also
compromised,  coexisting  with  LV  systolic  dysfunction  in  22
(62.9%)  patients.
LV  dilatation  (24%)  and  LV hypertrophy  (54.7%)  were  both
associated  with  aortic  valve  disease,  but  only the  former
with  mitral  disease.  The  left  atrium  was  dilated  in 79.4%  of
patients,  but  there  was  no  significant  association  with  aortic
or  mitral  valve  disease.  RV  dilatation  was  present  in 16.4%
of  cases  and  right  atrial  dilatation  in 47%;  both  conditions
were  associated  with  the presence  of  severe  TR.
Cardiac devices
Forty-eight  (16.7%)  patients  had  a  cardiac  device in place
prior  to  the  index  admission:  a  pacemaker  (PM)  in 30  (10.5%),
an  implanted  cardioverter-defibrillator  (ICD) in  10  (3.5%),
and  a  cardiac  resynchronization  therapy  (CRT)  device  in
eight  (2.7%)  patients.  Severe  chronic  TR  was  documented
in  62.5%  of  these patients,  and  was  associated  with  mitral
valve  disease  in 21  (43.8%;  significant  chronic  MR in 50%  of
these)  and with  aortic  valve  disease  in 10  patients  (20.8%;
moderate  or  severe  AS in 41.7%).
In  addition,  in  55  patients  (19.2%)  a device  was  implanted
for  the first  time  during  the  index  hospitalization:  a  PM  in
51  (17.8%)  patients,  an ICD  in two  (0.7%),  and  a CRT  pace-
maker  in another  two.
Associations  between  valvular  heart disease
and demographic, clinical and functional data
Aortic valve disease
Disease  of  the aortic  valve  showed no  gender  predominance,
but  correlated  directly  with  age  (p<0.001),  degenerative  eti-
ology  (p<0.001)  and presence  of HF  (p=0.004),  AF (p=0.014),
LV  dilatation  (p=0.003),  and LV  hypertrophy  (p<0.001).  There
was  no  significant  association  between  aortic  valve disease
and rheumatic  etiology,  reduced  LVEF,  left atrial  (LA)  dilata-
tion,  AV  block  or  bundle  branch  block  (p=NS  for  all).
Mitral  valve  disease
Mitral  disease  was  more  frequent  in  women  than  in  men
(58.9%  vs.  41.1%,  p=0.002),  and  was  associated  directly
with  rheumatic  etiology  (p=0.011),  ischemic  heart  dis-
ease  (p<0.001),  HF  (p=0.001),  AF  (p<0.001),  LV  dilatation
(p<0.001)  and  reduced  LVEF (p=0.003).  No  significant  asso-
ciation  was  found  between  mitral  valve  disease  and  LA
dilatation.
Tricuspid  valve regurgitation
The  presence  of moderate-to-severe  TR  did  not  differ
between  genders  (p=0.702),  and  correlated  directly  with  age
(p<0.001)  and  with  the presence  of  previously  implanted
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cardiac  devices  (p<0.001).  The  latter  association  was
observed  only  when  TR  coexisted  with  aortic  or  mitral
disease  (of  any  etiology).  A significant  association  was
also  found  between  TR  and  mitral  disease  (p<0.001),  right
chamber  dilatation  (p<0.001),  AF  (p<0.001)  and  pulmonary
hypertension  (p<0.001),  but  not  with  chronic  pulmonary  dis-
ease.
Valve  intervention  procedures
Thirty-one  patients  (10.8%)  had  previously  undergone  valve
intervention  (repair  or  replacement),  most frequently  SAVR
(58.1%),  followed  by  mitral  valve  repair  (38.7%)  and  TAVI
(12.9%).  No patient  had  been  previously  submitted  to  per-
cutaneous  mitral  valve  intervention.
During  the  index hospitalization,  118  patients  (41.1%)
underwent  valve  intervention.  Percutaneous  procedures
were  the  most  frequently  performed  (74.6%),  mainly  TAVI
(65.3%);  surgical  replacement  was  performed  in 12.7%  of
patients  (aortic  valve  in  12  patients,  mitral  valve in four),
and  surgical  repair  in 5.9%  of cases  (mitral  valve  in four
patients  and  aortic  valve  in  three).  Percutaneous  mitral
valve  interventions  were  performed  in 11  (9.3%)  patients.
Regarding  the 31  patients  who  had  previously  undergone
valve  intervention,  most  were  admitted  with  decompen-
sated  HF  (48.4%),  16.1%  were  admitted  electively  for
another  valve  procedure,  and 6.5%  presented  with  infectious
endocarditis.  Furthermore,  35.5%  of  this population  under-
went  valve  intervention  again,  25.8%  on  the same  valve.
In-hospital  mortality  was  12.9%  in this  high-risk  population.
Of  note,  4 patients  underwent  CABG  during  the index
hospitalization,  and 2  also  underwent  SAVR.
Discharge  and  post-discharge  data
Overall,  mean  LOS  was  11.98±14.33 days.  Most  patients
were  discharged  home  from  hospital  (84.3%)  and  5.2%  were
transferred  to  another  hospital  (in their  area  of residence)
for  continued  care. Overall  in-hospital  mortality  was  9.8%
and  cardiovascular  mortality  was  8.7%.  Most  deaths  (33.3%)
occurred  in the context  of  ACS,  followed  by  advanced  refrac-
tory  HF  and  cardiogenic  shock  due  to  VHD  (29.6%),  and  to
severe  refractory  pulmonary  hypertension  (related  to  valve
disease  and/or  pulmonary  embolism)  in 7.4%.  Other  causes
of  death  were  infectious  endocarditis  of  prosthetic  valves
(7.4%)  or  devices  (3.7%),  acute  complications  after  pros-
thetic  valve  implantation  (surgical  or  percutaneous)  (7.4%),
and  pericardial  effusion  (3.7%).
Discussion
From  an  overall  analysis  of  the  data  on this population,  the
first  point  to  highlight  is  that  significant  VHD  has  no  gender
predominance,  a  finding  consistent  with  the  results  of large
population  studies.2--4 The  second  point is  the median  age of
the  population,  almost  10  years  older  than  those  included  in
the  Euro  Heart  Survey.4 According  to  Eurostat  2015  data,18
the  proportion  of  people  aged  65  years  or  more  in Portugal
was  20.5%,  compared  to  the overall  median  percentage  of
19%  in  Europe,  but  this  small difference  does  not  appear
to account  for  the  discrepancy.  The  most likely  explanation
is  that  the  Euro  Heart  Survey  included  both  inpatients  and
outpatients,  whereas  the cohort  presented  here  included
only  inpatients,  a population  with  more  advanced  and
severe  disease,  and  probably  also  an older  one  compared
to  VHD  patients  in an outpatient  setting.1,4 This  difference
would  also  explain  the 56%  of  patients  with  AS found  in  our
hospitalized  population  compared  to  the  43%  reported  in
the  Euro  Heart  Survey.4 Of  note,  we  found  a predominance
of  females  in patients  with  rheumatic  valve  disease  and
consequently  in patients  with  mitral  disease  (which  was
significantly  associated  with  the  latter),  and  rheumatic
etiology  mainly  affected  younger  patients.
Although  about  11%  of  included  patients  were  born  in
Portuguese-speaking  African  countries,  most  of  them  had
been  living  in  Portugal  for decades,  and it was  thus  impossi-
ble  to  compare  the epidemiology  of  valve  disease  in  Africa
and  Portugal.  In  the VALVAFRIC  study,  a prospective  hospital
registry  of patients  with  rheumatic  valve  disease  in  west  and
central  sub-Saharan  Africa,  40.2%  presented  with  moderate
to  severe  disease,  the median  age of  the population  was
29.3±15.6  years,  and female  gender  predominated  (60%).14
Decompensated  HF  was  the main  reason  for admission
in  our  reflecting  the  long-term  evolution  of  valve disease,
the  advanced  age  of  the population,  and the severity  of  the
clinical  condition  of  patients  with  VHD  needing  hospitaliza-
tion.  Additionally,  AF  and pulmonary  hypertension  related  to
valve  disease  were  both  frequent  conditions  with  significant
hemodynamic  consequences.  Underlying  the  clinical  impact
of  VHD,  a  significant  proportion  of  patients  also  presented
with  echocardiographic  evidence  of  LV hypertrophy  and/or
dilatation,  features  linked  to  an unfavorable  prognosis.19
Contrary  to  expectations,  neither  aortic  nor  mitral  valve
disease  was  significantly  associated  with  LA  dilatation,  high-
lighting  the  multiplicity  of  conditions  that  can  contribute  to
alterations  in  atrial  architecture  and function.
Aging  is  associated  with  degenerative  changes  that  affect
not  only  the aortic  annulus  but  also  the conduction  sys-
tem,  and  complete  AV  block  was  another  frequent  reason  for
hospital  admission,  particularly  in patients  with  degenera-
tive  AS,  and  was  a common  indication  for  PM  implantation.
Advanced  AV  block  was  also  present  in  many  patients  with
MR,  albeit  less  frequently,  as  it may  occur  as  a  consequence
of  CAD  and  fibrosis.
The  majority  of  patients  with  VHD  had  several  cardio-
vascular  risk  factors  and  multiple  comorbidities,  mostly
significant  CAD, another  frequent  cause  for  hospital  admis-
sion.  In a recent  retrospective  study,  Emren  et al.20
assessed  the  prevalence  of concurrent  CAD  in  241  patients
(51%  female)  who  underwent  surgery  due  to severe  VHD.
CAD  was  detected  in 57.7%  of  patients  with  AS  and  in 41.9%
of  those  with  MR.  CAD  and  severe  AS frequently  coexist,20--22
although  the significance  and  severity  of  CAD  in  AS may  be
particularly  difficult  to  assess.  Concomitant  CAD  had  a clini-
cal  negative  impact  in  our cohort,  being  responsible  for 33%
of  all-cause  in-hospital  mortality,  highlighting  the need  for
CAD  to  be  managed  concurrently  during  hospitalization  for
VHD.
Coronary  revascularization  at the  time  of aortic  valve
replacement  may  be associated  with  improved  long-term
survival  without  affecting  operative  risk  in some  patient
subsets.23 However,  this is  an open-ended  issue  and  most
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studies  looking  at the outcomes  of  CAD  and PCI  in patients
undergoing  TAVI  reveal  no benefit  in terms  of mortality  or
major  cardiovascular  events.22--27
A  significant  proportion  of  patients  (35%)  presented  with
TR  associated  with  other  valve  disease,  mostly  mitral  dis-
ease,  thus  showing  a  significant  association  with  rheumatic
disease  and  with  secondary  MR. Dilated  cardiomyopathy
was  particularly  observed,  in agreement  with  the  current
literature.1 Besides,  cardiac  devices  previously  implanted
in  the  right  heart  were  associated  with  development  of  TR,
as  previously  described,1 with  most  patients  also  having  MR.
Decision  for  intervention  in moderate-to-severe  secondary
TR  is  frequently  a  matter  of  debate,  being  recommended
when  left-sided  valve surgery  is indicated,  or  when  right  HF
is  manifest.8
In  the  index  hospitalization  40%  of  patients  under-
went  valve  intervention,  primarily  TAVI,  reflecting  recent
changes  in  the paradigm  regarding  valve  disease  mana-
gement.  Calcified  AS is  associated  with  a  higher  risk  of
myocardial  infarction,  stroke  and  death,  independently  of
traditional  cardiovascular  risk  factors,  and  since  there  is  no
effective  medical  approach  and five-year  survival  without
intervention  ranges  from  15%  to  50%,9 percutaneous  valve
interventions  are  increasingly  important  in the  setting  of
the  old,  frail  patient  with  multiple  comorbidities,  who  fre-
quently  is not  considered  suitable  for  surgery.6
In  summary,  the  findings  in  the  cohort  presented  herein
may  be  considered  a  real-world  picture  of  current  VHD
in  developed  countries.  Globally,  VHD  is  most  commonly
degenerative,  mainly  affects  the elderly  with  multiple
comorbidities,  is  severe  and  has already  run  a  long  course.
It  is  frequently  associated  with  CAD,  HF,  AF and advanced
conduction  disease,  and  has an unfavorable  impact  on  prog-
nosis.  This  includes  quality  of  life  (particularly  symptoms
and  long  LOS)  and  in-hospital  mortality.  Valve  intervention
is  often  necessary,  and  the  percutaneous  approach  is  a  ther-
apeutic  option  in many  of  these  high-risk  patients.
Limitations
The  data  presented  are derived  from  a  single center  and  may
not  reflect  the circumstances  of  other  centers  specializing
in  the  management  of patients  with  VHD. Furthermore,  the
information  was  not  acquired  in  the  setting  of  a prospec-
tive  registry,  but consists  of  retrospective  data  collected
from  clinical  files  and  echocardiographic  reports,  which  in
some  cases  may  not  be  as  detailed  as  would  be  desirable.
However,  the  data  collected  reflect  the  actual  profiles  of
patients  hospitalized  with  VHD  in  the cardiology  ward  of a
tertiary  hospital,  and  the thorough  manual  analysis  and  mul-
tiple  revisions  performed  provide  a precise  and objective
set  of real-world  information,  similar  in general  respects  to
previous  work  published  in  this  field.
The influence  of  the different  variables  on mortality  was
not  studied,  as  this was  beyond  the  scope  of this  study.  Our
aim  was  to  characterize  the  profiles  of  patients  with  VHD
currently  admitted  to  a  tertiary  hospital  in contemporary
Europe,  in  which  the  new  therapeutic  options  for  patients
with  VHD  are  available,  and where  the European  guidelines
for the  treatment  of  heart  disease  are  applied.
Conclusion
On the  basis  of  the data  presented,  two  main  profiles
can  be delineated  for  patients  currently  hospitalized  with
VHD:  a dominant  one, characterized  by  the elderly  patient,
male  or  female,  with  multiple  comorbidities,  admitted  with
decompensated  HF  in the  setting  of  degenerative  AS,  pre-
senting  with  LV  hypertrophy  and/or  dilatation  but  with
preserved  LVEF,  frequently  with  AF,  who  is  preferably  treated
by  TAVI;  and  a  second,  less  prevalent  profile,  that  of a
younger  patient,  predominantly  female,  also  admitted  with
decompensated  HF  but  in the  setting  of  functional  mitral
regurgitation  (secondary  to  ischemic  heart  disease  or  dilated
cardiomyopathy),  also  presenting  with  AF  and  LV dilatation
but  with  reduced  LVEF,  who  less  often  undergoes  valve  inter-
vention,  but is  treated  medically  for  HF.  Of  note,  common
denominators  of  both  profiles  were  HF  and  AF.
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Appendix 1.
ICD-9  (International  Classification  of  Diseases)  diagnosis  of
valve  diseases  used:
394.0 (rheumatic  mitral  stenosis),  394.1  (rheumatic
mitral  regurgitation),  394.2  (rheumatic  mitral  stenosis  with
insufficiency),  394.9 (other  and unspecified  mitral  valve  dis-
eases),  395.0  (rheumatic  aortic  stenosis),  395.1  (rheumatic
aortic  insufficiency),  395.2  (rheumatic  aortic  stenosis  with
insufficiency),  395.9  (other  and  unspecified  rheumatic  aor-
tic  diseases),  396.0 (mitral  valve  stenosis  and  aortic  valve
stenosis),  396.1  (mitral  valve  stenosis  and aortic  valve
insufficiency),  396.2  (mitral  valve  insufficiency  and aortic
valve  stenosis),  396.3  (mitral  valve  insufficiency  and  aortic
valve  insufficiency),  396.8  (multiple  involvement  of  mitral
and  aortic  valves),  396.9  (mitral  and aortic  valve  diseases,
unspecified),  397.0  (diseases  of  tricuspid  valve),  397.1
(rheumatic  diseases  of  pulmonary  valve),  397.9  (rheumatic
diseases  of  endocardium,  valve  unspecified),  424.0  (mitral
valve  disorders),  424.1  (aortic  valve  disorders),  424.2 (tri-
cuspid  valve  disorders,  specified  as  nonrheumatic),  424.3
(pulmonary  valve  disorders)  and/or  424.9  (endocarditis,
valve  unspecified).
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